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doi:10.1016/j.jfma.2011.06.015Background/Purpose: Data on hospitalized novel influenza A (H1N1) infected children are
limited and urgently in demand. We conducted a clinical study to identify clinical features
and risk factors associated with severe novel H1N1 infections of children in Taiwan.
Methods: From July 24, 2009 to December 4, 2009, data from 61 hospitalized children infected
with 2009 novel H1N1 were collected. Demographics, underlying medical conditions, clinical
data, receipt of antiviral therapy, need for intensive care and outcome were analyzed to iden-
tify clinical features and risk factors of severe infections.
Results: Of the 61 inpatients, the male to female ratio was 41 to 20 and the most common age
group was between 6 and 12 years (36%). Almost all (98%) patients had fever, 53 (87%) patients
received oseltamivir treatment and 51% of them received oseltamivir within 48 hours. Four-
teen (23%) needed intensive care and 3 died. Obesity (a Body Mass Index  25 kg/m2 in children
 2 years of age, or a body weight  the 95th percentile in children <2 years of age), dyspnea,
C-reactive protein (CRP) > 3 mg/dL, pleural effusion, and delayed antiviral therapy were
significantly associated with the need for intensive care and/or death.
Conclusion: Obesity, dyspnea, CRP > 3 mg/dL, pleural effusion, and delayed antiviral therapy
are significantly associated with severe novel H1N1 infections in children.
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Since April 15, 2009 and April 17, 2009, when the first two
cases of novel influenza A (H1N1) infection were identified in
two southern California counties, cases of H1N1 were docu-
mented throughout the world with most occurring in the
United States and Mexico at that time.1 Since then, the virus
has spread worldwide and there have been more than 213
countries and overseas territories or communities that re-
ported laboratory-confirmed cases of pandemic influenza
H1N12009.Given the evidenceof sustained community-level
outbreaks of novel H1N1 in more than one World Health
Organization (WHO) region, the WHO declared a global
pandemicof influenzaA (H1N1) on June 11, 2009, designating
the virus “pandemic influenza A (H1N1) 2009 virus”.2
Children younger than 5 years or with certain chronic
medical conditions are at increased risk for complications
and death from seasonal influenza.3e5 Frequently reported
complications due to seasonal influenza include pneu-
monia, seizure, and bronchitis in hospitalized children.6
However, data on hospitalized novel H1N1 virus infected
children are limited and urgently in demand.7e10Therefore,
we conducted a clinical study to identify clinical features
and risk factors associated with severe novel H1N1 infec-
tions of pediatric patients who were hospitalized for the
treatment of novel H1N1 influenza in Taiwan.Methods
Identification of novel H1N1 patients
At National Taiwan University Hospital in Taiwan, we
included patients who were hospitalized for laboratory-
confirmed novel H1N1 virus infections. Laboratory-
confirmed novel H1N1 virus infection was defined as
either positive influenza A virus isolation followed by posi-
tive novel H1N1 real-time reverse transcription-polymerase
chain reaction (RT-PCR), or positive rapid influenza A test
(QuickVue AþB test, Quidel, San Diego, CA, USA) followed
by a positive novel H1N1 real-time RT-PCR. Virus isolation
was performed following standardized protocol in the
virology laboratory of this tertiary medical center.
Data collection and study design
From July 24, 2009 to December 4, 2009, the patients were
identified through daily review of hospitalized pediatric
patients and their virological results at National Taiwan
University Hospital. We collected basic information on
demographics, underlying medical conditions, clinical signs
and symptoms, laboratory data, influenza-associated
complications such as invasive bacterial infections
(defined as isolation of a bacterial pathogen from blood or
cerebrospinal fluid), pneumonia (defined as lung infiltrate
or consolidation on chest X-ray), need for intensive care
unit (ICU) care, receipt of antiviral therapy and other
treatment, and final outcome. Underlying medical condi-
tions that increased an individual’s risk for complications
from influenza were abstracted from the admission history
and physical notes, and included the following: asthma,chronic cardiovascular disease, immunosuppressive condi-
tion or therapy, and neuromuscular or cognitive dysfunction
(broadly defined to include developmental delay, spinal
cord injuries or other forms of paralysis, cerebral palsy, and
autism). Secondary bacterial infections were defined as
positive bacterial blood culture, positive urine pneumo-
coccal antigen test, or positive bacterial culture obtained
from bronchoaveolar lavage.
For time calculations, the day of admission was consid-
ered to be hospital day 0. The Body Mass Index (BMI) was
calculated by the formula: weight in kilograms divided by
the square of the height in meters. Obesity was defined as
a BMI  25 kg/m2 in children  2 years of age, or a body
weight  the 95th percentile of the normal range in
children <2 years of age.
We divided the patients into two groups, one group
consisted of patients who did not need intensive care and
survived while the other group consisted of patients who
needed intensive care and/or died. The second group was
defined as the severe novel H1N1 infection group. We then
compared these two groups to identify risk factors for
severe novel H1N1 infection in children.
Statistics
Comparisons of selected parameters were performed using
the chi-square test with Yates correction for categorical
variables and by the MannWhitney U test for continuous
variables. All statistical analyses were performed with SPSS
version 16.0 (SPSS, Chicago, IL) for Windows. A p value
<0.05 was considered statistically significant.
This study was approved by the ethics committee of
National Taiwan University Hospital.
Results
Demographics and comorbidities
From July 24, 2009 to December 4, 2009, 61 children
infected with the 2009 H1N1 virus were hospitalized in
National Taiwan University Hospital. Table 1 shows patient
demographics and comorbidities. The most common age
group was 6 to 12 years (38%). Of the 61 patients, 25 (41%)
had underlying medical conditions. Immunocompromised
patients or those with immunosuppression status were the
most common underlying medical condition seen in chil-
dren (21%), cardiovascular disease was the second most
common (8%), and neurocognitive, neuromuscular, or
seizure disorders were seen in 7% of all patients.
Three children (5%) were obese. Two of the obese chil-
dren passed away and one was admitted to the ICU;
therefore, obesity in children was significantly associated
with the need for ICU care and/or death (p Z 0.008).
Clinical manifestations and laboratory findings
Symptoms at presentation are listed in Table 2. Shortness of
breath was found in 26% of all patients, 17% in patients
belonging to the group without ICU care, and 57% in those
belonging to the group with ICU care and/or death. Of all the
Table 1 Demographics and comorbidities.
Variablesa All (n Z 61) No need of intensive care
and recovery (n Z 47)
With intensive care
and/or death (n Z 14)
p
Male/Female, no. 41/20 30/17 11/3 0.48
Age, y
Median (range) 7.3 (0.118.1) 7.1 (0.117.3) 8.1 (0.618.1) 0.71
<1 8 (13) 6 (13) 2 (14) 0.76
12 8 (13) 5 (11) 3 (21) 0.55
35 8 (13) 7 (15) 1 (7) 0.76
611 22 (36) 18 (38) 4 (29) 0.73
1218 15 (25) 11 (23) 4 (29) 0.97
BMI 17.7 (3.6) 17.2 (2.8) 19.3 (5.5) 0.35
Obesityb 3/50 (6) 0/39 (0) 3/11 (27) 0.008
Comorbidities
Any 25 (41) 17 (36) 8 (57) 0.28
Asthma 2 (3) 1 (2) 1 (7) 0.94
Immunosuppression 13 (21) 10 (21) 3 (21) 0.72
CV disease 5 (8) 3 (6) 2 (14) 0.70
CNS anomaly 4 (7) 2 (4) 2 (14) 0.47
BMI Z body mass index; CNS Z central nervous system; CV Z cardiovascular system; ICU Z intensive care unit; SD Z standard
deviation.
a Data were expressed as number (%) or mean (SD).
b Body weight  95th percentile in children <2 years of age or BMI  25 kg/m2 in children  2 years of age.
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ciated with the need for ICU care and/or death (pZ 0.008).
Table 3 shows the laboratory data and radiographic
characteristics. We found that 50% of 12 patients with ICU
care and/or death had a C-reactive protein (CRP) value
>3 mg/dL, but only 11% of patients without ICU care had
a CRP value >3 mg/dL (pZ 0.008). Therefore, a higher CRP
level was also a significant parameter for severe novel H1N1
infection. More secondary bacterial infections were found
in the group with ICU care and/or death (p Z 0.03).
Of the 56 patients who underwent chest radiography, 45
(80%) patients had findings that were consistent with
pneumonia. Pleural effusion predicted severe novel H1N1
infection and occurred significantly more frequently in the
group with ICU care and/or death (p Z 0.02).Table 2 Clinical symptoms and signs of the patients.
Symptomsa All (n Z 61) No need of inte
and recovery (n
Fever 60 (98) 47 (100)
Fever  3 d 33 (54) 23/47 (49)
Cough 58 (95) 45 (96)
Rhinorrhea 34 (56) 30 (64)
Sore throat 18 (30%) 15 (32)
Headache 7 (11%) 7 (15)
Vomiting 12 (20%) 10 (21)
Diarrhea 8 (13%) 9 (15)
Abdominal pain 8 (13%) 7 (15)
Shortness of breath 16 (26%) 8 (17)
Malaise 18 (30%) 15 (32)
Myalgia 10 (16%) 10 (21)
Seizure 4 (7%) 2 (4)
a Data were expressed as number (%).Diagnosis, treatment and outcome
Of the 61 patients, 14 (21%) were admitted to the ICU and 3
died. Among these 14 patients with severe novel H1N1
infections, six required mechanical ventilation, two had
acute respiratory distress syndrome (ARDS), and two had
a clinical diagnosis of sepsis and shock.
Table 4 shows patient treatments: 53 (87%) received
oseltamivir antiviral drug treatment. The median time from
the onset of illness to the initiation of antiviral therapy was
2 days (range, 011 days); 51% of patients received anti-
viral therapy within 48 hours after the onset of symptoms.
The group with ICU care and/or death received antiviral
therapy significantly later than the group without ICU care
(p Z 0.035). Thirty-seven (61%) patients also receivednsive care
Z 47)
With intensive care and/or
death (n Z 14)
p
13 (93) 0.52
10/14 (71) 0.24
13 (93) 0.79
4 (29) 0.59
3 (21) 0.67
0 (0) 0.29
2 (14) 0.85
1 (7) 0.51
1 (7) 0.76
8 (57) 0.008
3 (21) 0.67
0 (0) 0.14
2 (14) 0.47
Table 3 Laboratory data and radiographic characteristics.
Laboratory dataa All (n Z 61) No need of intensive
care and recovery
(n Z 47)
With intensive care
and/or death (n Z 14)
p
WBC < 5000 cells/mL 28/61 (46) 21/47 (45) 7/14 (50) 0.96
WBC > 11000 cells/mL 9/61 (15) 5/47 (11) 4/14 (29) 0.22
Lymphocyte < 1000 cells/mL 23/61 (38) 17/47 (36) 6/14 (43) 0.89
Monocyte < 200 cells/mL 13/61 (21) 11/47 (23) 2/14 (14) 0.72
Anemiab 5/61 (8) 3/47 (6) 2/14 (14) 0.70
Platelets < 100,000 cells/mL 5/61 (8) 4/47 (9) 1/14 (7) 0.70
AST > 100 U/L 3/51 (6) 2/41 (5) 1/10 (10) 0.90
ALT > 100 U/L 1/38 (3) 1/28 (4) 0/10 (0) 0.59
CRP > 3 mg/dL 11/58 (19) 5/46 (11) 6/12 (50) 0.008
Novel H1N1 virus study
Positive, virus isolation 37/54 (69) 32/44 (73) 5/10 (50) 0.31
Positive, rapid test 36/48 (75) 30/36 (83) 6/12 (50) 0.05
Positive, both virus isolation and rapid test 24/42 (57) 21/34 (62) 3/8 (38) 0.40
HAI titer  40 22/31 (71) 19/26 (73) 3/5 (60) 0.96
Secondary bacterial infectionc 6/61 (10) 2/47 (4) 4/14 (29) 0.03
Chest X-ray
Clear 11/56 (20) 9/42 (21) 2/14 (14) 0.85
Infiltration 39/56 (70) 33/42 (79) 6/14 (43) 0.03
Patch 9/56 (16) 4/42 (10) 5/14 (36) 0.06
ARDS 1/56 (2) 0/42 (0) 1/14 (7) 0.56
Pleural effusion 3/56 (5) 0/42 (0) 3/14 (21) 0.02
ALT Z alanine aminotransferase; ARDS Z acute respiratory distress syndrome; AST Z aspartate transaminase; CRP Z c-reactive
protein; CXR Z chest X-ray; HAI Z hemagglutination inhibition; Hb Z hemoglobin; ICU Z intensive care unit; Lab Z laboratory;
WBC Z white blood cell.
a Data were expressed as the number of positive results/number tested (%).
b Anemia was defined as Hb < 10 mg/dL.
c Secondary bacterial infection refers to the evidence of a positive bacterial culture from the sterile site or positive urine pneumo-
coccus antigen: sputum from broncheoaveolar lavage d one with methicillin-resistant Staphylococcus aureus; one with Acinetobacter
baumannii; one with Moraxella catarrhalis; three positive for urine pneumococcus antigen in two patients with pneumonia and one
patient with acute sinusitis.
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without ICU care and 100% of patients with ICU care and/or
death (p Z 0.002).Risk factors associated with severe novel H1N1
infections
In comparison with the group without ICU care, the
group with severe novel H1N1 infections had a significantlyTable 4 Treatment of patients.
Type of treatmenta All (n Z 61) No need of i
care and rec
Antiviral treatment
Any 53/61 (87) 40/47 (85)
 2 days after onset 27/53 (51) 23/40 (58)
Days from onset 2 (011) 2 (08)
Antibiotic treatment 37/61 (61) 23/47 (49)
a Data were expressed as the number of patients/total number of phigher percentage of obesity, shortness of breath, CRP
levels >3 mg/dL, secondary bacterial infections, and
radiographically confirmed pleural effusion. In addition,
the time interval between the onset of symptoms and the
start of antiviral therapy was significantly longer in the
group with severe novel H1N1 infections. This group had
a significantly lower percentage of influenza-like illness,
which might reflect delayed suspicion or diagnosis of
influenza, resulting in deferred antiviral therapy. This
group was also more likely to receive antimicrobial agents,ntensive
overy (n Z 47)
With intensive care
and/or death (n Z 14)
p
13/14 (93) 0.76
4/13 (31) 0.18
4 (111) 0.035
14/14 (100) 0.002
atients (%) or as median (range).
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lihood of secondary bacterial infections.Discussion
We reported on hospitalized pediatric patients infected
with the 2009 novel H1N1 influenza virus during the 2009
pandemic in Taiwan. The pandemic strain of the H1N1 virus
caused severe illness in the pediatric group, which included
pneumonia, ARDS, shock, and encephalitis, resulting in ICU
admission of 21% of patients and death in 5% of patients.
This finding is similar to another study conducted in
Argentina in the pediatric group and a nationwide study
conducted in the United States.7e11
In our study, we found that obesity was a risk factor
associated with ICU admission and/or death in the pediatric
group. In a nationwide study in the US, it was found that the
prevalence of morbid obesity (26%) was higher in hospital-
ized adult H1N1 patients than in the estimated adult U.S.
population (5%).7 Another study included 10 patients with
novel influenza A (H1N1) virus infection and ARDS at
a tertiary-care ICU in Michigan and reported that among
these 10 patients, nine were obese (BMI > 30 kg/m2).12 In
a mouse model, diet-induced obese mice had significantly
higher mortality when they were infected with the seasonal
influenza virus compared with their leaner counterparts.13
It is our unique and new finding that obese children may
be particularly vulnerable to life-threatening H1N1 infec-
tions; clinicians should be aware of the potential of severe
novel H1N1 infections in obese children as well as in obese
adults. However, because there were only three cases of
obese children in our study, we need to conduct more
clinical studies or gather further evidence to prove that
obesity in children is an important risk factor for severe
novel H1N1 infection.
In this study, we found that shortness of breath is a poor
indicator for outcome, which is consistent with Jain et al.7
We suggest that novel H1N1 infected patients with short-
ness of breath or dyspnea should be closely monitored.
Regarding our laboratory findings, we found that a higher
CRP level could be an indicator for a more severe novel
H1N1 disease. The patients in the ICU/death group had
significantly higher CRP levels. This phenomenon stands for
a more severe inflammation condition in the selected
group, which would face a worse outcome.
During the 19571958 influenza pandemic, Louria et al
reported findings of diffuse bilateral infiltrates in patients
with primary influenza viral pneumonia, whereas lobar
infiltrates were seen in patients with secondary bacterial
infections.14 We noticed that patients without ICU admis-
sion tended to present as infiltrates but patients who were
admitted to the ICU or died tended to present with
a pneumonia patch, ARDS pattern, or pleural effusion, and
had more secondary bacterial infections with higher CRP
levels.
According to Jain et al,7 the significant variable that was
associated with a better outcome for novel H1N1 inpatients
was the receipt of antiviral drugs within 2 days after the
onset of illness. Louie et al10 also reported similar findings
in California. The Centers for Disease Control and Preven-
tion suggested that antiviral treatment is most effectivewhen it is started in the first 48 hours of illness onset.15 In
our study, we also found that patients without ICU care had
a significantly shorter interval between symptoms onset
and oseltamivir administration. Therefore, we suggest that
the treatment should be started empirically, based on
clinical judgment, as early as possible, even before defin-
itive diagnostic test results become available, i.e., treat-
ment should not wait for laboratory confirmation of
influenza.
In conclusion, we found that 21% of hospitalized children
infected with novel H1N1 needed ICU care and 5% of them
died. Children with obesity, shortness of breath,
CRP > 3 mg/dL, pleural effusion, and delayed antiviral
therapy carry a higher risk for severe infection and poorer
outcome. Cautious monitoring of these parameters and
early treatment may improve the outcome.Acknowledgments
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